Green Synthesis of l‑Cysteine-Functionalized rGO-Silver Nanoparticles for Enhanced Photocatalytic and Antibacterial Applications.

Yasamin Soltanifar, Rahmatollah Rahimi, Clive A Prestidge, Mahboubeh Hosseini-Kharat

Abstract read

In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yasamin SoltanifarDepartment of Chemistry, Iran University of Science and Technology, Tehran 16846-13114, Iran.

Rahmatollah RahimiDepartment of Chemistry, Iran University of Science and Technology, Tehran 16846-13114, Iran.ORCID https://orcid.org/0000-0003-4459-0578

Clive A PrestidgeClinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, South Australia 5000, Australia.ORCID https://orcid.org/0000-0001-5401-7535

Mahboubeh Hosseini-KharatClinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, South Australia 5000, Australia.ORCID https://orcid.org/0000-0001-5099-2712

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we developed an eco-friendly two-step synthesis of an l-cysteine/reduced graphene oxide-silver nanoparticle (l-Cys-rGO-AgNPs) hybrid material using l-cysteine and l-ascorbic acid as reducing agents. The successful formation and uniform distribution of AgNPs (20-40 nm) on rGO sheets were confirmed by FTIR, XRD, FESEM, and EDX analyses. The nanocomposite achieved 71% photocatalytic degradation of methylene blue and demonstrated potent antibacterial properties against

Identifiers

PMID41078772

DOI10.1021/acsomega.5c02666

PMCPMC12508982

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.